Humacyte, Inc. Common Stock (HUMA) is a publicly traded Healthcare sector company. As of May 20, 2026, HUMA trades at $0.86 with a market cap of $199.46M and a P/E ratio of -1.43. HUMA moved +4.64% today. Year to date, HUMA is -15.35%; over the trailing twelve months it is -62.99%. Its 52-week range spans $0.55 to $6.77. Analyst consensus is strong buy with an average price target of $2.27. Rallies surfaces HUMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes HUMA SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $0.86 |
| Market Cap | $199.46M |
| P/E Ratio | -1.43 |
| EPS | $-0.59 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.77 |
| 52-Week Low | $0.55 |
| Volume | 1.64M |
| Avg Volume | 0 |
| Revenue (TTM) | $2.02M |
| Net Income | $-97.59M |
| Gross Margin | -475.05% |
6 analysts cover HUMA: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $2.27.